Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:603998'
s EV-to-FCF Range Over the Past 10 Years
Min: -1591.16 Med: 18.72 Max: 3631.23
Current: 13.57
During the past 13 years, the highest EV-to-FCF of Hunan Fangsheng Pharmaceutical Co was 3631.23. The lowest was -1591.16. And the median was 18.72.
SHSE:603998's EV-to-FCF is ranked better than 67.91% of 561
companies
in the Drug Manufacturers industry
Industry Median: 21.29
vs SHSE:603998: 13.57
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hunan Fangsheng Pharmaceutical Co (SHSE:603998) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hunan Fangsheng Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Hunan Fangsheng Pharmaceutical Co's share price for today is ¥10.78.
Hunan Fangsheng Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hunan Fangsheng Pharmaceutical Co EV-to-FCF Related Terms
Hunan Fangsheng Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Fangsheng Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hunan Fangsheng Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hunan Fangsheng Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hunan Fangsheng Pharmaceutical Co's EV-to-FCF falls into.
Hunan Fangsheng Pharmaceutical Co's current Enterprise Value is ¥4,981 Mil.
Hunan Fangsheng Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥336 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Fangsheng Pharmaceutical Co (SHSE:603998) has a EV-to-FCF of 14.84 as of Aug. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hunan Fangsheng Pharmaceutical Co and its competitors. This is 21% below median its historical median of 18.72. According to the industry distribution chart, Hunan Fangsheng Pharmaceutical Co ranks #180 out of 561 companies in the Drug Manufacturers industry, placing it in the top 32.1%.
Is Hunan Fangsheng Pharmaceutical Co's EV-to-FCF too high?
Hunan Fangsheng Pharmaceutical Co's current EV-to-FCF of 14.84 is 21% below median its 10-year median of 18.72. The Drug Manufacturers industry median EV-to-FCF is 21.29. Hunan Fangsheng Pharmaceutical Co's value of 14.84 is 30.3% below this industry median. Based on the distribution chart, Hunan Fangsheng Pharmaceutical Co ranks #180 out of 561 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hunan Fangsheng Pharmaceutical Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hunan Fangsheng Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hunan Fangsheng Pharmaceutical Co ranks #180 out of 561 companies for EV-to-FCF. This puts Hunan Fangsheng Pharmaceutical Co in the upper half of its industry. The industry median EV-to-FCF is 21.29. Hunan Fangsheng Pharmaceutical Co's value of 14.84 is 30.3% below this benchmark. While the company's 10-year median is 18.72 vs. the industry median of 21.29, Hunan Fangsheng Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.29, based on 561 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hunan Fangsheng Pharmaceutical Co's current EV-to-FCF of 14.84 is 30.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hunan Fangsheng Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hunan Fangsheng Pharmaceutical Co's current EV-to-FCF is 14.84, which is 21% below median its own 10-year median of 18.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hunan Fangsheng Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hunan Fangsheng Pharmaceutical Co (SHSE:603998) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥12.06, compared to a current price of ¥10.78 — trading 10.6% below its estimated fair value. The current EV-to-FCF is 14.84, which is 21% below median its 10-year median of 18.72 and 30.3% below the Drug Manufacturers industry median of 21.29. Hunan Fangsheng Pharmaceutical Co's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hunan Fangsheng Pharmaceutical Co (SHSE:603998), the current EV-to-FCF is 14.84 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hunan Fangsheng Pharmaceutical Co (SHSE:603998) Overvalued in 2026?
Based on GuruFocus' analysis, Hunan Fangsheng Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥10.78 is trading 10.6% below its estimated GF Value™ of ¥12.06.
GuruFocus considers Hunan Fangsheng Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603998:
EV-to-FCF: 14.84 (21% below median its 10-year median of 18.72)
GF Value™: ¥12.06 vs. price of ¥10.78 (10.6% below fair value)
Industry Position: 30.3% below the Drug Manufacturers median (#180 of 561)
No single metric tells the full story. See the SHSE:603998 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hunan Fangsheng Pharmaceutical Co Ltd is engaged in pharmaceutical business. The company's business scope covers the production and sales of tablets, capsules, granules, oral suspension, powder, suppository, powder-injection, tinctures, spray lotion, small volume injections, and bulk pharmaceutical chemicals. Its product offerings include Cefixime Tablets, Cefpiramide for Injection, Cefprozil Tablets, Fleroxacin Dispersible Tablets, and others.
86GF Score
Get the complete analysis for SHSE:603998
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603998 has been successfully added to your 
